Why It Matters
This indicates that even major pharmaceutical companies face challenges with blockbuster drug performance directly impacting their financial results and market expectations.
Key Intelligence
- ■Roche's recent quarterly sales were lower than anticipated.
- ■The underperformance of a key 'blockbuster' eye drug was identified as a primary factor.
- ■This specific drug's sales decline held back the company's overall revenue growth for the quarter.